Danaher Corp
Close on Nov 2, 2026Market cap $160.26BP/E 40.5Yield –
Danaher Total Company Core Sales Growth (Non-GAAP) by Quarter
Total Company Core Sales Growth (Non-GAAP) (%)
Danaher Total Company Core Sales Growth (Non-GAAP): 3.0% in Q3 2026, unchanged from a year earlier.
Where the Q3 2026 figure comes from
Source: Danaher IR — nongaap_2026Q3 ↗
Core operating metric reflecting constant-currency organic revenue growth of segments/subsidiaries owned for ≥ 1 year.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total Company Core Sales Growth (Non-GAAP) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 3.0% | 0.0 pts | Danaher IR — nongaap_2026Q3 ↗ |
| Q2 2026 | Jun 30, 2026 | 3.0% | +1.5 pts | Danaher IR — nongaap_2026Q2 ↗ |
| Q1 2026 | Mar 31, 2026 | 0.5% | +0.5 pts | Danaher IR — nongaap_2026Q1 ↗ |
| Q4 2025 | Dec 31, 2025 | 2.5% | +1.5 pts | Danaher IR — nongaap_2025Q4 ↗ |
| Q3 2025 | Sep 30, 2025 | 3.0% | +2.5 pts | Danaher IR — nongaap_2025Q3 ↗ |
| Q2 2025 | Jun 30, 2025 | 1.5% | +5.0 pts | Danaher IR — nongaap_2025Q2 ↗ |
| Q1 2025 | Mar 31, 2025 | 0.0% | +4.0 pts | Danaher IR — nongaap_2025Q1 ↗ |
| Q4 2024 | Dec 31, 2024 | 1.0% | +12.5 pts | Danaher IR — nongaap_2024Q4 ↗ |
| Q3 2024 | Sep 30, 2024 | 0.5% | +14.5 pts | Danaher IR — nongaap_2024Q3 ↗ |
| Q2 2024 | Jun 30, 2024 | -3.5% | +5.5 pts | Danaher IR — nongaap_2024Q2 ↗ |
| Q1 2024 | Mar 31, 2024 | -4.0% | +2.0 pts | Danaher IR — nongaap_2024Q1 ↗ |
| Q4 2023 | Dec 31, 2023 | -11.5% | -19.5 pts | Danaher IR — nongaap_2023Q4 ↗ |
| Q3 2023 | Sep 30, 2023 | -14.0% | -24.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2023 | Jun 30, 2023 | -9.0% | -18.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2023 | Mar 31, 2023 | -6.0% | -19.0 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2022 | Dec 31, 2022 | 8.0% | -18.5 pts | Danaher IR — nongaap_ex_veralto ↗ |
| Q3 2022 | Sep 30, 2022 | 10.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q2 2022 | Jun 30, 2022 | 9.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q1 2022 | Mar 31, 2022 | 13.0% | – | Danaher IR — nongaap_ex_veralto ↗ |
| Q4 2021 | Dec 31, 2021 | 26.5% | – | Danaher IR — nongaap_ex_veralto ↗ |
Breakdown
What makes up total Company Core Sales Growth (Non-GAAP)
- Core Growth ex-Respiratory5.5% · Q3 2026
- Contribution / Headwind from Cepheid Respiratory Testing to Total Company Core Sales Growth2.5% · Q3 2026
- Base Business Core Sales Growth (Legacy FY2021Q4–FY2023Q4: Base Business ex-COVID Testing & Vx/Tx)-4.5% · Q4 2023
- COVID-19 Testing & Vaccines/Therapeutics Demand Impact (Legacy FY2021Q4–FY2023Q3)10.0% · Q3 2023
- Price Realization Impact on Total Company Sales Growth (10-K)–
- Acquisitions Impact on Total Company Sales Growth (Annual series; quarters without M&A are left blank by the company)–
- Currency Exchange Impact0.0% · Q3 2026
- Reported GAAP Sales Growth8.5% · Q3 2026
Cite this data
StockData. (2026). Danaher Total Company Core Sales Growth (Non-GAAP) (%), quarterly Q4 2021–Q3 2026 [Data set]. Compiled from Danaher SEC filings and investor materials. https://stockdatahq.com/stocks/dhr/kpis/core-sales-growth-total
See every metric in the Danaher KPI table. Data updated Nov 2, 2026.